Dermatology

NeuClone Completes Early Testing for Psoriasis Biosimilar

April 8th 2020

By The Center for Biosimilars

Article

NeuClone said phase 1 patient monitoring and blood sampling has been completed for its ustekinumab biosimilar candidate, which is targeted at the $6.6 billion in annual revenue earned by Stelara, a Janssen Pharmaceutical Companies product.

Alvotech Hf and DKSH Announce Plans to Bring an Adalimumab Biosimilar to Market

March 26th 2020

By The Center for Biosimilars

Article

Alvotech Hf and DSH hope to get an adalimumab biosimilar approved in the United States, Europe, and selected Southeast Asia markets.

Study: Adalimumab Plus Hydroxychloroquine Leads to Hair Regrowth in Lichen Planopilaris

February 27th 2020

By Skylar Jeremias

Article

Lichen planopilaris (LPP) is a type of scarring hair loss that occurs when lichen plaus, a relatively common inflammatory skin disease, affects areas of skin where hair grows. It destroys the hair follicle and replaces it with scarring, resulting in permanent hair loss. LPP’s causes and pathology are unknown.

2019 Saw Mounting Evidence to Support Nonmedical Switching, Review Article Says

February 21st 2020

By Deana Ferreri, PhD

Article

A recent year-in-review article outlines studies published in 2019 about nonmedical switching from originator biologics to biosimilars in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.

AbbVie: Next-Generation Skyrizi and Rinvoq Are Showing Traction in Humira Space

February 21st 2020

By Skylar Jeremias

Article

Pharmaceutical giant AbbVie reports strong revenues for next-generation products the company hopes will provide fill-in revenue as Humira (adalimumab) sales decline and more biosimilars to the blockbuster arthritis drug enter the market.

No Higher Risk of Cancer for Patients With Psoriasis Treated With Biologics, Analysis Finds

February 19th 2020

By The Center for Biosimilars Staff

Article

The review found no increased risk of cancer when looking at both keratinocyte cancer and lymphomas in patients on biologics vs conventional therapy. Overall, however, patients with psoriasis appear to have a slightly increased risk of certain cancers.

Animal Study of Secukinumab Biosimilar Gene Therapy Yields Promising Results

January 25th 2020

By Deana Ferreri, PhD

Article

The study examined secukinumab biosimilar lentivirus-based gene therapy, which showed successful and prolonged expression of the recombinant antibody in rats.

Canadian Organizations Gather Stakeholders to Stimulate Biosimilar Acceptance

December 18th 2019

By The Center for Biosimilars Staff

Article

The pan-Canadian Pharmaceutical Alliance engaged the Canadian Agency for Drugs and Technologies in Health to lead a multiphase stakeholder consultation process to encourage biosimilar uptake.

Bispecific Antibody Outperforms Adalimumab in Phase 3 Study in Psoriasis

December 17th 2019

By The Center for Biosimilars Staff

Article

No biosimilar adalimumab launches are currently announced for the US market prior to 2023 as a result of patent settlements struck between biosimilar developers and Humira’s maker, AbbVie, and new data show that innovative biologics currently being developed may be able to provide superior benefits versus the older adalimumab product that may make biosimilars of this therapy less appealing treatment choices.

Novartis' Secukinumab Narrowly Misses End Point in Trial Against Adalimumab

November 1st 2019

By Allison Inserro

Article

Novartis Friday announced results from a head-to-head trial of its secukinumab (Cosentyx) versus adalimumab in patients with active psoriatic arthritis (PsA), saying its therapy missed statistical significance for its primary end point.